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Abstract: Clostridium perfringens epsilon toxin (Etx) is a pore-forming toxin responsible for a
severe and rapidly fatal enterotoxemia of ruminants. The toxin is classified as a category B
bioterrorism agent by the U.S. Government Centres for Disease Control and Prevention (CDC),
making work with recombinant toxin difficult. To reduce the hazard posed by work with
recombinant Etx, we have used a variant of Etx that contains a H149A mutation (Etx-H149A),
previously reported to have reduced, but not abolished, toxicity. The three-dimensional structure of
H149A prototoxin shows that the H149A mutation in domain III does not affect organisation of the
putative receptor binding loops in domain I of the toxin. Surface exposed tyrosine residues in
domain I of Etx-H149A (Y16, Y20, Y29, Y30, Y36 and Y196) were mutated to alanine and mutants
Y30A and Y196A showed significantly reduced binding to MDCK.2 cells relative to Etx-H149A that
correlated with their reduced cytotoxic activity. Thus, our study confirms the role of surface
exposed tyrosine residues in domain I of Etx in binding to MDCK cells and the suitability of
Etx-H149A for further receptor binding studies. In contrast, binding of all of the tyrosine mutants to
ACHN cells was similar to that of Etx-H149A, suggesting that Etx can recognise different cell
surface receptors. In support of this, the crystal structure of Etx-H149A identified a glycan
(b-octyl-glucoside) binding site in domain III of Etx-H149A, which may be a second receptor binding
site. These findings have important implications for developing strategies designed to neutralise
toxin activity.
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Introduction
Epsilon toxin (Etx) is a pore-forming toxin and is
produced by Clostridium perfringens strains belong-
ing to toxinotypes B and D.1 These strains are
responsible for enterotoxemia, which affects mainly
sheep but also occurs in goats and cattle, and results
in heavy economic losses.2,3 The disease is also
known as overeating disease as it is often triggered
by feeding on carbohydrate-rich food, leading to dis-
ruption of the microbial balance in the intestine and
consequent proliferation of C. perfringens and over-
production of Etx.4
By an unknown mechanism, Etx crosses the gut
wall, enters into the bloodstream and is dissemi-
nated to several organs, in particular to the kidneys
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and the brain, where intoxication results in fluid
accumulation due to increased permeability of blood
vessels.4 There is also evidence that Etx acts directly
on the brain,5–7 targeting glutamatergic neurons8
and stimulating glutamate release. This may explain
some of the neurological symptoms often associated
with the disease in sheep, such as loss of coordina-
tion and seizures.3,9,10
Etx is secreted by C. perfringens as a prototoxin
(P-Etx), which consists of 296 amino acids with a
molecular weight of 32,981 Da.11 The prototoxin is
activated, with carboxy-terminal and amino-terminal
peptides removed, by proteolytic cleavage in the gut,
either by digestive proteases of the host, such as
trypsin and chymotrypsin,12 or by k-protease pro-
duced by C. perfringens.13,14
The crystal structure of P-Etx has been deter-
mined15 and reveals mainly b-sheets, which are
organized into three functional domains. Domain I
at the N-terminus contains the suggested receptor
interaction region,15,16 domain II contains an amphi-
pathic b-hairpin, which is predicted to play a role in
membrane insertion, and domain III at the C-termi-
nus contains the C-terminal peptide, which has to
be removed for activation.
The mechanism of pore formation by Etx is not
well understood and the current pore formation
model is based on studies of other b-pore-forming
toxins (b-PFTs), such as aerolysin from Aeromonas
hydrophila.17 Like aerolysin, Etx binds to detergent-
resistant microdomains (DRMs) of lipid rafts.18–20
Both P-Etx and Etx can accumulate within DRMs
but only activated toxin can oligomerize and form a
heptameric complex. Heptameric complexes of Etx
have been identified in rat synaptosomal, MDCK
and mpkCCDcl4 cell membranes.
21–23 The final step
of pore formation might involve unfolding of the am-
phipathic b-hairpin in domain II and subsequent
insertion of the toxin into the membrane, usually
leading to rapid cell death.
Etx is unique among b-PFTs as it shows high
cell specificity and potency. Relatively few cell lines
are susceptible to the toxin and most in vitro studies
on Etx have been carried out using the highly sus-
ceptible Madin–Darby Canine Kidney (MDCK) cell
line.24,25 Other toxin-sensitive cell lines include the
mouse kidney cell line mpkCCDcl4
23 and the recently
identified human renal adenocarcinoma cell line
ACHN.26 Because of its high potency, and the poten-
tial to use Etx as a bioterrorist weapon, the toxin is
classified as a category B bioterrorism agent by the
U.S. Government Centres for Disease Control and
Prevention.27
In view of the high potency of Etx, the aim of
this study was to identify a platform that provided a
reduction in the hazard associated with the genetic
manipulation of recombinant C. perfringens epsilon
toxin in Escherichia coli whilst allowing receptor
binding studies. For this platform we selected the
H149A variant of Etx (numbering corresponds to
prototoxin without the 13 amino acids N-terminal
peptide), which reduces toxicity sixfold in MDCK
cells and 67-fold in mice.28 This study has confirmed
the role of tyrosine residues in domain I of Etx in
binding to MDCK cells and has also revealed that
additional receptor binding regions appear to play a
role in toxicity of Etx.
Results
Mutation H149A does not affect P-Etx structure
To determine the effect of the H149A mutation on
the tertiary structure of P-Etx, we crystallized
recombinant P-Etx-H149A. Initial trials resulted in
crystals, which grew in the presence of 0.85 to 1.0 M
ammonium dihydrogen phosphate and diffracted to
3 A˚. However, the crystals were twinned with
>45% twin fractions. In an attempt to reduce the
degree of twinning, various additives were included
in the crystallization conditions. One of the addi-
tives, b-octyl-glucoside (b-OG), resulted in crystals
with lower twin fractions, and which diffracted to
2.4 A˚. They belonged to the P3 spacegroup with unit
cell dimensions of a5123.70 A˚, b5 123.70 A˚,
c5127.31 A˚, and a5b5 90, g5120. The asym-
metric unit (ASU) contained four P-Etx-H149A mole-
cules, four b-OG molecules and four ordered
phosphates. Due to the higher resolution of the
P-Etx-H149A data compared with the original wild-
type structure (PDB ID: 1UYJ, 2.6 A˚) we detected a
11 residue register error in the wild-type structure
from Ser3 to Gly14 (corresponds to Ser16 to Gly27
in PDB ID: 1UYJ).
Each b-OG molecule is accommodated in a cleft
formed between two b-sheets in domain III of P-Etx-
H149A and interacts through hydrogen bonds to Etx
[Fig. 1(A), lower inset]. Specifically, the glucose moiety
of b-OG forms hydrogen bonds via O5 to Thr93 main
chain N and through O2 to Val72 mainchain O. In
addition, in chains A and B, the O3 of b-OG forms a
hydrogen bond to OE1 of Glu61 in the neighboring
asymmetric unit. The alkyl chain of b-OG is in close
proximity to Phe92 in all four Etx molecules. The four
phosphate molecules also form hydrogen bonds to Etx
through OD1 and OD2 of Asp48, OG of Ser188, and
NE2 of Gln85 from the neighboring ASU. Moreover,
strong positive density (>3 r) in the Fo-Fc map could
be seen near Y29 in all four chains in the ASU, and
although the size of this density suggests additional
bound b-OG molecules we could not place b-OG with
certainty (data not shown).
The P-Etx-H149A structure closely resembles
the wild-type structure with a Ca-Ca root mean
square deviation (RMSD) of 0.95 A˚ [Fig. 1(B)]. Small
main chain deviations occur in domains I, II and III
compared to the wild-type structure. In domain I, at
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the end of the first a-helix near Y29, the Ca posi-
tions are shifted by 2.20 A˚ in respect to the wild-
type structure. This may be due to the influence by
putative b-OG molecules in this region as mentioned
above. In addition, a loop between Ser195 and P200
is shifted by up to 2.58 A˚ away from the core of the
molecule. In domain II, the membrane-inserting b-
hairpin is shifted by up to 2.84 A˚ near Phe135.
Finally, in domain III, the b-strand from V70 to N79
is displaced outwards by up to 2.05 A˚ in order to
accommodate the b-OG molecule [Fig. 1(A), lower
inset]. Overall, the H149A mutation does not have
an effect on the prototoxin tertiary structure and
does not induce any significant conformational
changes in the suggested receptor binding loops in
domain I. Collection and refinement statistics for
the crystals are listed in Table I, and coordinates
and structure factors have been deposited with the
Protein Data Bank (PDB ID: 3ZJX).
Tyrosine mutants in H149A background mimic
the binding of tyrosine mutants in wild-type
background
Surface exposed tyrosine residues in domain I of Etx
have recently been reported to play a role in binding
to MDCK cells.16 To evaluate the suitability of P-
Figure 1. Structure of C. perfringens epsilon prototoxin P-Etx-H149A. (A) Cartoon representation of the prototoxin colored
according to domain. The likely membrane-inserting b-hairpin is colored red. The C-terminal peptide is colored in yellow and
situated near the pink oligomerization domain. Top inset shows the receptor binding region and the positions of the mutated
tyrosines. The lower inset shows the location of A149 (blue spheres), the bound b-OG ligand and interacting residues. Amino
acid numbering corresponds to prototoxin without the 13 amino acids N-terminal peptide sequence. (B) Superposition of wild-
type prototoxin (PDB ID: 1UYJ, grey) with P-Etx-H149A (blue). Asterisks indicate the areas of highest RMS Ca-Ca deviation.
Table I. X-Ray Data Collection and Refinement
Statistics
P-Etx-H149A
Data collection
Space group P3
Cell dimensions
a, b, c (A˚) 123.70, 123.70, 127.31
a,b,g () 90, 90, 120
Resolution (A˚) 21.56–2.40 (2.49–2.40)a
Rmerge 0.061 (0.435)
I/rI 12.3 (1.2)
Completeness (%) 100.0 (99.9)
Redundancy 3.70 (2.25)
Refinement
Resolution (A˚) 21.56–2.4
No. reflections 85,072
Rwork/Rfree (%) 24.6–27.5
No. atoms
Protein 8448
Ligand/ion 100
Water 459
B-factors (A˚2)
Protein 54.5
Ligand 48.2
Water 47.0
RMS deviations
Bond lengths (A˚) 0.01
Bond angles () 1.33
a Values in parentheses are for highest-resolution shell.
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Etx-H149A for receptor binding studies, we selected
six surface exposed tyrosine residues (Y16, Y20,
Y29, Y30, Y36, and Y196) in domain I for site-
directed mutagenesis and replaced each one with al-
anine [Fig. 1(A), top inset] to delete the side chain
completely, and thus to allow a definitive determina-
tion of whether the side chain contributed to binding
in any way.
Recombinant P-Etx-H149A (Fig. 2) and its
derivatives were expressed and purified as described
in Materials and Methods. All tyrosine mutants
showed similar purification [Fig. 3(A)] and trypsin
digestion [Fig. 3(B)] profiles to Etx-H149A, indicat-
ing that tyrosine mutations do not affect the folding
of the toxin. Purified recombinant P-Etx-H149A and
its derivatives have an apparent molecular weight of
37 kDa as detected by SDS-PAGE [Fig. 3(A)]. Ther-
mal stability assay29 revealed that the melting tem-
perature (Tm) of the tyrosine mutants was similar to
that of P-Etx-H149A [Fig. 3(C)], providing further
evidence that the tyrosine mutants are folded
correctly.
On-Cell Western assays were used to evaluate
the effect of the tyrosine mutations on the binding of
P-Etx-H149A to MDCK.2 cells. The binding activity
of each tyrosine mutant was expressed as the fold-
change in fluorescence intensity relative to P-Etx-
H149A (Fig. 4). Mutants Y30A and Y196A showed
significant reduction in binding activity relative to
P-Etx-H149A (20-fold and 6-fold decrease in fluores-
cent intensity, respectively).
Reduced binding of tyrosine mutants to
MDCK.2 cells correlates with their reduced
cytotoxicity
Next, we evaluated the effect of the tyrosine muta-
tions on the cytotoxic activity of trypsin-activated
Etx-H149A towards MDCK.2 cells by measuring the
amount of lactate dehydrogenase (LDH) released
from the cytosol of lysed cells into the cell culture
medium. All tyrosine mutations resulted in reduced
cytotoxic activity of Etx-H149A towards MDCK.2
cells [Fig. 5(A)], indicated by a right shift of the dose
response curves relative to Etx-H149A. The dose of
each toxin that killed 50% of the cells (CT50) was
determined by nonlinear regression analysis and the
cytotoxic activity of each tyrosine mutant was
expressed as the fold-change in CT50 relative to Etx-
H149A. Mutants Y30A and Y196A showed signifi-
cant reduction in cytotoxic activity toward MDCK.2
cells relative to Etx-H149A (27-fold and 10-fold
increase in CT50, respectively) [Fig. 5(B)].
Surface exposed tyrosine residues in domain I
do not play a role in binding of P-Etx-H149A to
ACHN cells
To determine whether surface exposed tyrosine resi-
dues in Domain I also play a role in binding of Etx
to ACHN cells, we tested binding of the tyrosine
mutants in H149A background to ACHN cells using
the On-Cell Western assay. The binding activity of
each tyrosine mutant was expressed as the fold-
change in fluorescence intensity relative to P-Etx-
H149A. ACHN cells treated with all of the tyrosine
mutants showed fluorescence similar to that of cells
treated with P-Etx-H149A (Fig. 6), indicating that
surface exposed tyrosine residues in Domain I do
not mediate binding of Etx to ACHN cells.
Next, we measured LDH release from ACHN
cells exposed to mutants Y30A and Y196A, mutants
Table II. The Reduced Binding Ability of the Tyrosine
Mutants Correlates with Their Reduced Ability to Bind
to MDCK.2 Cells
Etx-H149A
mutant
Mean fold-change
in CT50 relative to
Etx-H149A
Mean fold-change
in fluorescence
intensity relative
to P-Etx-H149A
Y30A 27.86 7.3*** 220.76 4.5***
Y196A 9.16 2.1** 26.062.6**
Y36A 5.762.6 23.76 1.5
Y29A 4.162.2 23.36 0.6
Y16A 3.562.9 21.76 0.6
Y20A 2.561.3 21.36 0.6
The binding activity of each Tyr mutant was expressed as
the fold-change in fluorescence intensity relative to P-Etx-
H149A as determined in Figure 4. The cytotoxic activity of
tyrosine mutants was expressed as the fold-change in CT50
relative to Etx-H149A as determined in Figure 5(B). Statis-
tically significant differences are indicated by asterisks.
Figure 2. Schematic representation of recombinant C. perfringens epsilon prototoxin P-Etx-H149A. The amino acid sequences
around the processing sites are shown. Amino acid numbering for H149A corresponds to prototoxin without the 13 amino acids
N-terminal peptide sequence.
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that showed significantly reduced binding and cyto-
toxic activities toward MDCK.2 cells. The results of
our cytotoxicity assay revealed that Etx-H149A and
its derivatives are unable to cause cell lysis in
ACHN cells, while wild-type Etx was able to cause
approximately 45% cell lysis at the maximum dose
of 10mM tested (Fig. 7).
Discussion
Epsilon toxin is a potent toxin and is classified as a
category B bioterrorism agent,30 making genetic
modification of the toxin hazardous. In this study,
we showed that the H149A mutation does not affect
the overall organisation of the putative receptor
binding loops in domain I. Residue H149 is located
in Domain III of Etx in close proximity to the tip of
the b-hairpin in Domain II. Therefore, the H149A
mutation is likely to interfere with the conformation
changes associated with insertion of the b-hairpin
into the membrane and thus with membrane inser-
tion of the toxin. It has previously been shown that
creating disulphide bonds between pairs of intro-
duced cysteines (one in the b-hairpin and one in an
adjacent strand) prevented pore formation but not
receptor binding or oligomerization of the toxin,31
providing further support that interfering with pore
formation of Etx does not affect its receptor binding.
Our cytotoxicity and binding data show that res-
idues Y30 and Y196 play an important role in cell
binding and thus, cytotoxicity of Etx toward
MDCK.2 cells. All of the tyrosine mutants that we
have cloned, expressed and purified in H149A back-
ground were soluble and stable, and our thermal
stability analysis indicated that these proteins are
correctly folded, ruling out the possibility that the
reduced binding and cytotoxic activities of the tyro-
sine mutants towards MDCK.2 cells was due to their
change in structure. The average CT50 for Etx-
H149A towards MDCK.2 cells was 400 ng/mL (12
nM), in agreement with the reported CT50 of 20 to
300 ng/mL for the more active wild-type
Etx.22,23,25,32 We also showed that tyrosine mutants
in H149A background mimic the behavior of tyrosine
mutants in wild-type background,16 confirming the
role of domain I in binding of Etx to MDCK cells,
and thus the suitability of the H149A mutant for
further receptor binding studies.
The human kidney carcinoma cell line, ACHN,
has recently been identified to be susceptible to
Etx26 but the role of surface exposed tyrosine resi-
dues in binding of Etx to this cell line has not been
determined. Using the H149A mutant as a platform
to study binding of tyrosine mutants to ACHN cells
we showed that surface exposed tyrosine residues in
domain I of Etx do not mediate binding of Etx to
ACHN cells, suggesting that alternative amino acids
within the toxin contribute to binding of Etx to these
cells. The crystal structure of P-Etx-H149A also
identified a glycan (b-octyl-glucoside) binding site in
domain III of Etx-H149A, suggesting the presence of
a secondary binding site in Etx in this region.
Recent evidence also indicates the presence of a
Figure 3. Recombinant tyrosine mutants in H149A background are folded correctly. Inactive prototoxins (A) and trypsin
activated toxins (B) were separated by SDS-PAGE and visualized by Coomassie staining. Arrows indicate the positions of
monomeric epsilon prototoxins and trypsin-activated toxins, respectively. (C) Thermo-stability of P-Etx-H149A and its
derivatives were determined by the Boltzmann method using the Protein Thermal Shift software (Applied Biosystems).
Figure 4. Effect of tyrosine substitutions on the binding of P-
Etx-H149A to MDCK.2 cells. The binding of tyrosine mutants
to MDCK.2 cells was determined by the On-Cell Western
assay. Statistically significant differences between P-Etx-
H149A and tyrosine mutant proteins are indicated by
asterisks.
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secondary binding site for lysenin, a sphingomyelin-
specific pore-forming protein,33 in a location similar
to the b-OG binding site in Etx.
The results of our cytotoxicity assay also revealed
that ACHN cells are more resistant to Etx induced cell
lysis than MDCK.2 cells. Wild-type Etx in ACHN cells
was only able to cause up to 45% cell lysis, even at the
maximum dose of 10 mM tested, while a dose of wild-
type Etx approximately 10,000-fold less is able to cause
50% cell lysis in MDCK.2 cells,22,23,25,32 suggesting that
the mechanism of Etx-induced intoxication in ACHN
and MDCK cells is different. Several lines of evidence
suggest that Etx-induced cytotoxicity differs in different
cell lines. In particular, Chassin et al.23 reported that
Etx-induced intracellular Ca21 rise and ATP depletion-
mediated rapid cell death in mpkCCDcl14 cells occurred
even under conditions that prevented toxin oligomeriza-
tion and pore formation, providing evidence that pore
formation is not the only way Etx manifests its cytotoxic-
ity. The differences in the relative sensitivity of MDCK.2
and ACHN cells to Etx are likely to be due to the differ-
ences in the mode of action of Etx on these two cell
lines, probably due to the ability of Etx to recognise dif-
ferent targets on the cell surface of different cells.
There is no evidence for a single receptor for ep-
silon toxin. Studies using MDCK cells suggest that
binding of Etx is mediated by O-linked oligosaccha-
rides as removal of O-glycans by b-elimination
reduced binding of Etx to these cells.34 Other studies
implicated that interaction of Etx with target cells is
mediated by the O-linked glycans of the extracellu-
lar domain of the human hepatitis A virus cellular
receptor (HAVCR1).16,26 Although disrupting expres-
sion of HAVCR1 in MDCK and ACHN cells led to
increased resistance to Etx-induced cytotoxicity,26
providing good evidence that both of these cell lines
express HAVCR1, no direct evidence exists that the
toxin binds to HAVCR1 on these cells. Furthermore,
studies using synaptosomal fractions isolated from
rat brain indicate that the receptor for Etx in the
brain is a sialoglycoprotein.35 In this study, we pro-
vide further indirect evidence that Etx binds to gly-
cans by identifying a b-OG binding site in-between
two b-sheets in domain III. In addition, a second un-
identified ligand, likely to be b-OG, was found in the
proximity of Y29 in domain I, providing further
circumstantial evidence for the role of domain I in
glycan binding.
Figure 5. Effect of the tyrosine mutations on the cytotoxic
activity of Etx-H149A toward MDCK.2 cells. (A) The cytotoxic
activity of trypsin-activated toxins toward MDCK.2 cells was
determined by measuring the release of lactate dehydrogen-
ase (LDH) from lysed cells. (B) The dose of each toxin that
killed 50% of the cells (CT50) was determined and cytotoxic
activity of tyrosine mutants was expressed as the fold-
change in CT50 relative to Etx-H149A. Statistically significant
differences between Etx-H149A and tyrosine mutant
proteins are indicated by asterisks.
Figure 6. Effect of the tyrosine mutations on the binding of
P-Etx-H149A to ACHN cells. The binding of tyrosine mutants
to ACHN cells was determined by the On-Cell Western
assay.
Figure 7. Effect of tyrosine substitutions on the cytotoxicity
of Etx-H149A toward ACHN cells. The cytotoxic activity of
trypsin-activated toxins towards ACHN cells was determined
by measuring the release of LDH from lysed cells. Results
were normalized to the signal from cells treated with PBS
only (0% lysis) and cells treated with 0.9% (v/v) Triton X-100
(100% lysis).
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In conclusion, the present study confirmed the role
of surface exposed tyrosine residues in binding of Etx to
MDCK.2 cells and demonstrated the suitability of the
H149A mutant for further receptor binding studies.
However, we found no evidence that surface exposed ty-
rosine residues in domain I mediate binding of Etx to
ACHN cells, suggesting that Etx recognises different tar-
gets on the cell surface of different cells. These findings
have important implications for developing strategies
designed to neutralise the activity of this potent toxin.
Materials and Methods
Cell culture
MDCK.2 cells (ATCC-LGC Standards, Teddington,
UK) and ACHN cells (ECACC, Salisbury, UK) were
routinely cultured in Eagle’s Minimum Essential
Medium (EMEM; ATCC-LGC Standards, Teddington,
UK) supplemented with 10% Foetal Bovine Serum
Gold (PAA, Pasching, Austria) at 37C in a humidi-
fied atmosphere of 95% air/5% CO2. The culture
medium was replaced every 2 to 3 days. Cells were
routinely detached by incubation in trypsin/EDTA
and split as appropriate (typically 1:6 dilutions).
Cloning of recombinant epsilon prototoxin
P-Etx-H149A
The etxD gene encoding epsilon prototoxin with the
H149A mutation (P-Etx-H149A) was subcloned from
plasmid pCl028 into the expression vector pET-26b(1)
(Merck, Darmstadt, Germany) using NcoI and XhoI
restriction sites. This fused the N-terminal end of P-
Etx-H149A without the 13 N-terminal residues
(KEISNTVSNEMSK) to the PelB leader peptide, while
the C-terminal end of P-Etx-H149A was fused to a pol-
yhistidine (63His) affinity tag to aid purification of
recombinant P-Etx-H149A (Fig. 2). The recombinant
plasmid expressing P-Etx-H149A is termed pET26-
b(1)/P-Etx-H149A. All amino acid numbering corre-
sponds to prototoxin with the 13 amino acids N-termi-
nal peptide sequence removed, unless otherwise stated.
Site-directed mutagenesis
Mutations were introduced into the gene encoding
P-Etx-H149A using the QuickChange Lightning
Site-Directed Mutagenesis Kit (Agilent Technologies,
Inc., Santa Clara) according to the manufacturer’s
instructions. Synthetic oligonucleotide primer pairs
(Eurofins MWG Operon, Ebersberg, Germany) were
used to change each tyrosine codon to an alanine
codon. To create Tyr mutants, plasmid pET26-b(1)/
P-Etx-H149A served as template. The presence of
the intended mutations was verified by DNA
sequencing (Source BioScience, Cambridge, UK).
Expression and purification of P-Etx-H149A and
its derivatives
For expression of P-Etx-H149A and its derivatives,
recombinant plasmids were transferred into E. coli
Rosetta 2 (DE3) cells (Merck, Darmstadt, Germany)
and expression of P-Etx-H149A and its derivatives
was induced using the autoinduction system as
described by Studier.28 In brief, cells (100 mL) were
grown in ZYM-5052 autoinducing medium supple-
mented with 50lg/mL kanamycin and 34lg/mL
chloramphenicol and cultured at 37C for 3 h at 300
rpm, then for a further 24 h at 20C, 300 rpm.
For protein purification, cells were harvested by
centrifugation and 2 g of cell pellet was lysed by 10
mL BugBusterTM Protein Extraction Reagent
(Merck, Darmstadt, Germany) containing 10 mL rly-
sozymeTM (1 KU/mL) (Merck, Darmstadt, Germany)
and 10 mL BenzonaseVR Nuclease (25 U/mL) (Merck,
Darmstadt, Germany). The cell suspension was incu-
bated on a rotating mixer for 25 min at room tem-
perature and centrifuged at 16,000g for 20 min at
4C to separate soluble and insoluble fractions. The
supernatant was loaded onto a His GraviTrap col-
umn (GE Healthcare Life Sciences, Little Chalfont,
UK) following the manufacturer’s guidelines. In
brief, His-tagged proteins were bound to the affinity
column using a buffer composed of 20 mM sodium
phosphate, 500 mM NaCl, 20 mM imidazole, pH 7.4.
The column was washed with a buffer composed of
20 mM sodium phosphate, 500 mM NaCl, 60 mM
imidazole, pH 7.4. Recombinant prototoxin was
eluted in a buffer composed of 20 mM sodium phos-
phate, 500 mM NaCl, 500 mM imidazole, pH 7.4. All
purification steps were carried out at 4C. For buffer
exchange and sample clean up, prototoxin contain-
ing eluate was applied to a PD-10 Desalting Column
(GE Healthcare Life Sciences, Little Chalfont, UK)
and eluted in 10 mM phosphate buffer, 2.7 mM
potassium chloride, 137 mM NaCl, pH 7.4. Protein
concentrations were determined using the BCA
assay (Fisher Scientific UK Ltd, Loughborough,
UK).
The purity of P-Etx-H149A and its derivatives
was confirmed by SDS-PAGE. Proteins were
resolved by 4 to 12% Bis-Tris NuPAGE gels (Invitro-
gen Ltd., Paisley, UK) using Surelock Xcell appara-
tus (Invitrogen Ltd., Paisley, UK) and NuPAGE
MES SDS running buffer (Invitrogen Ltd., Paisley,
UK). All samples were heated before loading at 70C
for 10 min in NuPAGE LDS sample buffer (Invitro-
gen Ltd., Paisley, UK). Gels were run at 200 V for
45 min. After electrophoretic separation, proteins
were visualised by SimplyBlue staining (Invitrogen
Ltd., Paisley, UK). The Perfect ProteinTM Marker, 10
to 225 kDa (Merck, Darmstadt, Germany) was used
as the molecular weight standard.
Crystallization and data processing
For crystallization experiments a modified construct
of P-Etx-H149A was used with a TEV cleavable N-
terminal His-tag and a Factor Xa cleavage (IEGR)
site engineered in between amino acids K260 and
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K261, which allows potential activation of P-Etx-
H149A by Factor Xa. Purification of P-Etx-H149A
was carried out using standard metal affinity chro-
matography followed by removal of the N-terminal
His-tag by TEV protease. A final size exclusion chro-
matography step was performed using a 120 mL
Superdex S-200 column equilibrated with 20 mM
Tris pH 7.5, 150 mM NaCl, and 1 mM DTT.
Recombinant P-Etx-H149A was concentrated to 16
mg/mL using a 10 kDa cut-off Amicon concentrator
(Merck, Darmstadt, Germany). Crystals were
obtained using the hanging drop method in 0.85 M
ammonium dihydrogen phosphate and 0.5% (w/v)
b-octyl-glucoside (b-OG). Data were collected on
a Rigaku Saturn 944 CCD detector mounted onto a
Rigaku Micromax X-ray generator. Data were
indexed and integrated and scaled with D*TREK.36
Molecular replacement was carried out using Phaser
MR37 as part of the CCP4 package38 using the wild-
type structure (PDB ID: 1UYJ) as a search model.
Refinement was carried out using Refmac 5,39 and
manual building and real space refinement was per-
formed using COOT.40 Model validation was calcu-
lated using Molprobity41 and PyMOL42 was used for
visualisation and figure preparation.
Activation of P-Etx-H149A and its derivatives by
trypsin
Purified recombinant P-Etx-H149A and its deriva-
tives were activated with trypsin, TPCK treated
from bovine pancreas (Sigma-Aldrich Company Ltd.,
Gillingham, UK), which removes the C-terminal
peptide sequence, together with the His-tag (Fig. 1).
Trypsin was prepared in PBS and added to recombi-
nant prototoxin at 1:100 (w/w) ratio and incubated
at room temperature for 1 h. Protease Inhibitor
Cocktail, EDTA-Free (Fisher Scientific UK Ltd,
Loughborough, UK) was added to the digest to
inhibit trypsin in the samples. Removal of the
C-terminal peptide sequence was assessed by SDS-
PAGE.
Protein thermal shift assay
Thermostability of P-Etx-H149A and its derivatives
was assessed by mixing purified recombinant proto-
toxin (0.25 mg/mL) with 2403 SYPRO Orange dye
(Sigma) in triplicate and fluorescence was monitored
using a StepOnePlus quantitative PCR machine
(Applied Biosystems) with a 1% thermal gradient
from 25C to 99C. Fluorescence data was analysed
by the Protein Thermal Shift Software (Applied Bio-
systems) to calculate the Tm using the Boltzmann
method.
Cytotoxicity assay
The cytotoxic activity of trypsin-activated Etx-
H149A and its derivatives toward MDCK.2 and
ACHN cells was determined by measuring the
amount of lactate dehydrogenase (LDH) released
from the cytosol of lysed cells into the cell culture
medium using the CytoTox 96 nonradioactive cyto-
toxicity assay kit (Promega, Southampton, UK)
according to the manufacturer’s protocol. In brief, a
twofold dilution series of each activated toxin (rang-
ing from 10 mM to 0.15 nM) was prepared in PBS
and added to cells seeded into 96-well plates (33 104
cells/well). Following incubation at 37C for 3 h, cell
culture medium (50 mL) was harvested from cell
monolayers, transferred to a fresh 96-well enzymatic
assay plate and 50 lL of reconstituted substrate mix
was added to each well. The plate was incubated for
30 min at room temperature, protected from light.
Absorbance was measured at 490 nm using a Model
680 Microplate Reader (Bio-Rad Laboratories Ltd.,
Hemel Hempstead, UK). The absorbance values for
each sample were normalized by subtracting the
absorbance value obtained for the culture medium
from untreated cells. The toxin dose required to kill
50% of the cell monolayer (CT50) was determined by
nonlinear regression analysis, fitting a variable
slope log(dose) versus response curve, constraining F
to a value of 50 (logCT505 logCTF2 (1/HillSlope)3
log(F/(1002F)).
On-Cell Western assay
On-Cell Western assay was used to measure binding
of P-Etx-H149A and its derivatives to MDCK.2 and
ACHN cells. Black 96-well microtiter plates were
seeded with 33 104 cells/well in EMEM medium
containing 10% foetal bovine serum. To allow cells to
attach, plates were incubated overnight at 37C in a
humidified atmosphere of 95% air/5% CO2. The next
day, plates were washed with PBS and cells were
incubated with purified recombinant prototoxin (10
mM) for 1 h at 37C in a humidified atmosphere of
95% air/5% CO2. For background control, triplicate
wells were incubated with PBS only. Unbound toxin
was removed by washing cell monolayers three
times with PBS. Cells were then fixed with 4% form-
aldehyde at room temperature for 20 min. After
washing the cell monolayers with PBS three times,
cells were blocked for 1.5 h using Odyssey blocking
buffer (LI-COR Biosciences, Lincoln, NE). Bound
prototoxin was detected with mouse anti-His Tag
monoclonal antibody (Invitrogen Ltd., Paisley, UK)
and IRDye 800CW goat anti-mouse IgG (H1L) anti-
body (LI-COR Biosciences, Lincoln) at 1:500 dilution
each. Plates were imaged at 800 nm using the Odys-
sey CLx infrared imaging system (LI-COR Bioscien-
ces, Lincoln) to quantify the amount of fluorescent
signal. The fluorescent signal from wells treated
with prototoxin was normalized to that of wells
treated with PBS only and the binding activity of
each tyrosine mutant was expressed as the
fold-change in fluorescence intensity relative to P-
Etx-H149A.
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Statistical analysis
To compare the means of protein thermal shift,
On-Cell Western and cytotoxicity data, one-way
ANOVA analysis followed by Dunnett’s post test
(***P<0.001, **P< 0.01) was carried out using the
GraphPad Prism software 5.01 (GraphPad Software,
La Jolla). In all analyses, a P value of less than 0.01
was considered significant. All data represent the
means and standard deviations of three independent
experiments performed in triplicate.
Accession numbers
The structure coordinates of P-Etx-H149A have been
deposited at the Protein Data Bank (http://www.
pdb.org), PDB ID: 3ZJX. Amino acid numbering cor-
responds to prototoxin with the 13 amino acids N-
terminal peptide sequence.
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